PEG-ASP+Gemox Regimen and Thalidomide for NK/T Lymphoma
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
Extranodal natural killer/T-cell lymphoma (ENKTL) is an aggressive form of non-Hodgkin's
lymphoma and shows extremely poor survival. This prospective pilot study to evaluate the
efficacy and safety of long-acting aspargase (pegylated aspargase, PEG-ASP) combined with
gemcitabine and oxaliplatin (PASP -Gemox) treatment in this population.